<DOC>
	<DOC>NCT02230228</DOC>
	<brief_summary>This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.</brief_summary>
	<brief_title>Phase 1 Safety Study of ALK-001 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Dystrophies</mesh_term>
	<criteria>Main Inclusion Criteria Adult between 21 and 70 years old (inclusive) Healthy subject, as judged by investigator Subject is able and willing to comply with study requirements (study medication compliance, schedule of followup visits) Subject has provided informed consent to participate If female, subject uses a medically accepted birth control method and agrees to use such a method for entire clinical trial period Main Subject has taken disallowed items during the past 30 days Female with a positive urine pregnancy test at screening Lactating woman Subject has participated in any clinical study involving an investigational drug, biologic or device, during the past 30 days History or current evidence of gastrointestinal malabsorption Subject has any other medical condition, which in the opinion of the investigator, is likely to prevent compliance with protocol and/or interfere with successful collection of study Subject has, in the opinion of investigator, clinically significant laboratory result(s), positive drug or alcohol screening, or ECG, which makes subject unsuitable for participation.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>